The United Kingdom is hardening its stance on industry issues.
May 1, 2005
By:
Sarah Houlton
A recently released report claims pharma hides bad clinical trial results and over-promotes drugs. Tougher regs are being called for.
|
Novartis rivals Teva for the top spot in generics manufacturing.
Apr 1, 2005
By:
Sarah Houlton
Conventional wisdom says that generics businesses are a drain on valuable resources. But these units are much less prone to the disastrous drug safety panics that Big Pharma has recently endured.
|
EMEA's head wants a separate safety agency. Is that a good thing?
Mar 1, 2005
By:
Sarah Houlton
Pharma companies in Europe believe that it already takes too long for new medicines to reach patients. Separate bodies for efficacy and safety will lead to further delays.
|
A new report identifies 17 conditions that need better therapies.
Jan 1, 2005
By:
Sarah Houlton
Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.
|
The UK government extracts more pharma price concessions
Dec 1, 2004
By:
Sarah Houlton
The British trade association says the cuts are unnecessary because drug prices have fallen in real terms by 10-15 percent during the last 10 years while the UK government's budget has remained steady.
|
Medical journals call for the publication of all clinical trials.
Nov 1, 2004
By:
Sarah Houlton
If trial results never reach the public, researchers could waste time repeating lines of inquiry that have already proven unsuccessful.
|
After a 10-year absence, counterfeit drugs turn up in the United Kingdom.
Oct 1, 2004
By:
Sarah Houlton
The fakes likely entered the market through internet commerce, yet the government seems to be encouraging online pharmacies by discussing a shakeup of retail drugstores.
|
The UK government cracks down again on animal rights protesters.
Sep 1, 2004
By:
Sarah Houlton
Between January and June this year, 45 UK vendors capitulated to the activists and stopped supplying pharma companies.
|
Nov 1, 2002
By:
Sarah Houlton
Current lawmakers make frown on cannabis use, but for thousands of years people used it to treat conditions as diverse as rheumatism, convulsions, tumors, and pain. Now the small, private UK company Oxford Natural Products has completed Phase I trials on a cannabis derivative for treating post-operative and cancer pain.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
